216 related articles for article (PubMed ID: 34452327)
1. An Epitope Platform for Safe and Effective HTLV-1-Immunization: Potential Applications for mRNA and Peptide-Based Vaccines.
Lucchese G; Jahantigh HR; De Benedictis L; Lovreglio P; Stufano A
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452327
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial screening algorithm to engineer multiepitope subunit vaccine targeting human T-lymphotropic virus-1 infection.
Pandey RK; Ojha R; Chatterjee N; Upadhyay N; Mishra A; Prajapati VK
J Cell Physiol; 2019 Jun; 234(6):8717-8726. PubMed ID: 30370533
[TBL] [Abstract][Full Text] [Related]
3. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
4. Epitope-based universal vaccine for Human T-lymphotropic virus-1 (HTLV-1).
Raza MT; Mizan S; Yasmin F; Akash AS; Shahik SM
PLoS One; 2021; 16(4):e0248001. PubMed ID: 33798232
[TBL] [Abstract][Full Text] [Related]
5. Combined cytolytic effects of a vaccinia virus encoding a single chain trimer of MHC-I with a Tax-epitope and Tax-specific CTLs on HTLV-I-infected cells in a rat model.
Ohashi T; Nakamura T; Kidokoro M; Zhang X; Shida H
Biomed Res Int; 2014; 2014():902478. PubMed ID: 24791004
[TBL] [Abstract][Full Text] [Related]
6. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection.
Mulherkar R; Karabudak A; Ginwala R; Huang X; Rowan A; Philip R; Murphy EL; Clements D; Ndhlovu LC; Khan ZK; Jain P
Vaccine; 2018 Aug; 36(33):5046-5057. PubMed ID: 30005946
[TBL] [Abstract][Full Text] [Related]
8. An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
Tu JJ; King E; Maksimova V; Smith S; Macias R; Cheng X; Vegesna T; Yu L; Ratner L; Green PL; Niewiesk S; Richner JM; Panfil AR
J Virol; 2024 Feb; 98(2):e0162323. PubMed ID: 38193692
[TBL] [Abstract][Full Text] [Related]
9. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus).
Kazanji M; Heraud JM; Merien F; Pique C; de Thé G; Gessain A; Jacobson S
J Gen Virol; 2006 May; 87(Pt 5):1331-1337. PubMed ID: 16603536
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
[TBL] [Abstract][Full Text] [Related]
11. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.
Kampylafka EI; Alexopoulos H; El Hamidieh A; Dalakas MC; Andreakos E; Tzioufas AG
Autoimmunity; 2015; 48(7):453-9. PubMed ID: 26287441
[TBL] [Abstract][Full Text] [Related]
12. Short communication an interferon-γ ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population.
Best I; López G; Talledo M; MacNamara A; Verdonck K; González E; Tipismana M; Asquith B; Gotuzzo E; Vanham G; Clark D
AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1207-12. PubMed ID: 21453202
[TBL] [Abstract][Full Text] [Related]
13. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1.
Kabiri M; Sankian M; Hosseinpour M; Tafaghodi M
Int J Pharm; 2018 Oct; 549(1-2):404-414. PubMed ID: 30075250
[TBL] [Abstract][Full Text] [Related]
14. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells.
Kannagi M; Shida H; Igarashi H; Kuruma K; Murai H; Aono Y; Maruyama I; Osame M; Hattori T; Inoko H
J Virol; 1992 May; 66(5):2928-33. PubMed ID: 1373197
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of HCV-E2 Glycoprotein Epitope Mimics in Molecular Construction of Potential Synthetic Vaccines.
Meuleman TJ; Cowton VM; Patel AH; Liskamp RMJ
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672697
[TBL] [Abstract][Full Text] [Related]
16. HTLV-1, Immune Response and Autoimmunity.
Quaresma JA; Yoshikawa GT; Koyama RV; Dias GA; Fujihara S; Fuzii HT
Viruses; 2015 Dec; 8(1):. PubMed ID: 26712781
[TBL] [Abstract][Full Text] [Related]
17. Human T cell lymphotropic virus: necessity for and feasibility of a vaccine.
de Thé G; Bomford R; Kazanji M; Ibrahim F
Ciba Found Symp; 1994; 187():47-55; discussion 55-60. PubMed ID: 7796676
[TBL] [Abstract][Full Text] [Related]
18. Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection.
Mahieux R; Horal P; Mauclère P; Mercereau-Puijalon O; Guillotte M; Meertens L; Murphy E; Gessain A
J Clin Microbiol; 2000 Nov; 38(11):4049-57. PubMed ID: 11060067
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H
J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298
[TBL] [Abstract][Full Text] [Related]
20. Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I.
Goon PK; Igakura T; Hanon E; Mosley AJ; Barfield A; Barnard AL; Kaftantzi L; Tanaka Y; Taylor GP; Weber JN; Bangham CR
J Immunol; 2004 Feb; 172(3):1735-43. PubMed ID: 14734756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
